Arcus Biosciences, Inc. (RCUS) Return on equity 2018–2025
Arcus Biosciences, Inc. (RCUS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-55.9%FY2025 · since FY2018: -21.1% → -55.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -55.9% | +2.4 pp |
| FY2024 | -58.4% | +8.1 pp |
| FY2023 | -66.5% | -25.8 pp |
| FY2022 | -40.6% | -46.9 pp |
| FY2021 | 6.3% | +30.8 pp |
| FY2020 | -24.5% | +27.2 pp |
| FY2019 | -51.7% | -30.5 pp |
| FY2018 | -21.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RCUS financial trends
RCUS RevenueRCUS Net incomeRCUS Net marginRCUS Gross profitRCUS Gross marginRCUS Operating incomeRCUS Operating marginRCUS Operating cash flowRCUS Free cash flowRCUS Capital expendituresRCUS Stock buybacksRCUS Dividends paidRCUS Total assetsRCUS Total liabilitiesRCUS Shareholders’ equityRCUS overview →